JP2003521528A5 - - Google Patents

Download PDF

Info

Publication number
JP2003521528A5
JP2003521528A5 JP2001556812A JP2001556812A JP2003521528A5 JP 2003521528 A5 JP2003521528 A5 JP 2003521528A5 JP 2001556812 A JP2001556812 A JP 2001556812A JP 2001556812 A JP2001556812 A JP 2001556812A JP 2003521528 A5 JP2003521528 A5 JP 2003521528A5
Authority
JP
Japan
Prior art keywords
medicament according
plasma
cure
glucose concentration
medicament
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
JP2001556812A
Other languages
English (en)
Japanese (ja)
Other versions
JP2003521528A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/DK2001/000075 external-priority patent/WO2001056959A1/en
Publication of JP2003521528A publication Critical patent/JP2003521528A/ja
Publication of JP2003521528A5 publication Critical patent/JP2003521528A5/ja
Withdrawn legal-status Critical Current

Links

JP2001556812A 2000-02-01 2001-02-01 食事補強剤、又は非インシュリン依存性糖尿病、高血圧及び/又は代謝症候群の治療のための薬剤の調製に使用する物質 Withdrawn JP2003521528A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
DKPA200000163 2000-02-01
DK200000163 2000-05-08
PCT/DK2001/000075 WO2001056959A1 (en) 2000-02-01 2001-02-01 A substance for the use in a dietary supplementation or for the preparation of a medicament for the treatment of non-insulin dependent diabetes mellitus, hypertension and/or the metabolic syndrome

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2012112329A Division JP2012153721A (ja) 2000-02-01 2012-05-16 食事補強剤に使用するための、又は非インシュリン依存性糖尿病、高血圧及び/又は代謝症候群の治療のための薬剤の調製のための、物質

Publications (2)

Publication Number Publication Date
JP2003521528A JP2003521528A (ja) 2003-07-15
JP2003521528A5 true JP2003521528A5 (https=) 2009-06-25

Family

ID=8159060

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2001556812A Withdrawn JP2003521528A (ja) 2000-02-01 2001-02-01 食事補強剤、又は非インシュリン依存性糖尿病、高血圧及び/又は代謝症候群の治療のための薬剤の調製に使用する物質
JP2012112329A Pending JP2012153721A (ja) 2000-02-01 2012-05-16 食事補強剤に使用するための、又は非インシュリン依存性糖尿病、高血圧及び/又は代謝症候群の治療のための薬剤の調製のための、物質

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2012112329A Pending JP2012153721A (ja) 2000-02-01 2012-05-16 食事補強剤に使用するための、又は非インシュリン依存性糖尿病、高血圧及び/又は代謝症候群の治療のための薬剤の調製のための、物質

Country Status (8)

Country Link
US (5) US20030060428A1 (https=)
EP (2) EP1255718A1 (https=)
JP (2) JP2003521528A (https=)
CN (1) CN100475757C (https=)
AU (1) AU784422B2 (https=)
BR (1) BR0108043A (https=)
CA (2) CA2762121A1 (https=)
WO (1) WO2001056959A1 (https=)

Families Citing this family (42)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2001056959A1 (en) 2000-02-01 2001-08-09 Stevia Aps A substance for the use in a dietary supplementation or for the preparation of a medicament for the treatment of non-insulin dependent diabetes mellitus, hypertension and/or the metabolic syndrome
EP1648483B1 (en) * 2003-06-30 2008-06-04 Nestec S.A. Composition for treating and/or preventing insulin resistance
AT502270B1 (de) * 2005-02-21 2007-07-15 Emakos Naturnahe Nahrungsmitte Verfahren zum modifizieren von steviosid durch austauschreaktionen
US8956677B2 (en) * 2005-11-23 2015-02-17 The Coca-Cola Company High-potency sweetener composition with glucosamine and compositions sweetened therewith
US20070134391A1 (en) * 2005-11-23 2007-06-14 The Coca-Cola Company High-Potency Sweetener Composition for Treatment and/or Prevention of Autoimmune Disorders and Compositions Sweetened Therewith
US9101160B2 (en) 2005-11-23 2015-08-11 The Coca-Cola Company Condiments with high-potency sweetener
US8367138B2 (en) * 2005-11-23 2013-02-05 The Coca-Cola Company Dairy composition with high-potency sweetener
US8956678B2 (en) * 2005-11-23 2015-02-17 The Coca-Cola Company High-potency sweetener composition with preservative and compositions sweetened therewith
US8940350B2 (en) * 2005-11-23 2015-01-27 The Coca-Cola Company Cereal compositions comprising high-potency sweeteners
US8435588B2 (en) * 2005-11-23 2013-05-07 The Coca-Cola Company High-potency sweetener composition with an anti-inflammatory agent and compositions sweetened therewith
US8940351B2 (en) * 2005-11-23 2015-01-27 The Coca-Cola Company Baked goods comprising high-potency sweetener
EP1971228A1 (en) * 2005-11-23 2008-09-24 The Coca-Cola Company Natural high-potency sweetener compositions with improved temporal profile and/or flavor profile, methods for their formulation, and uses
US20070116831A1 (en) * 2005-11-23 2007-05-24 The Coca-Cola Company Dental Composition with High-Potency Sweetener
US20070116822A1 (en) * 2005-11-23 2007-05-24 The Coca-Cola Company High-potency sweetener composition with saponin and compositions sweetened therewith
US20070116836A1 (en) * 2005-11-23 2007-05-24 The Coca-Cola Company High-Potency Sweetener Composition for Treatment and/or Prevention of Osteoporosis and Compositions Sweetened Therewith
US8993027B2 (en) * 2005-11-23 2015-03-31 The Coca-Cola Company Natural high-potency tabletop sweetener compositions with improved temporal and/or flavor profile, methods for their formulation, and uses
US8524303B2 (en) * 2005-11-23 2013-09-03 The Coca-Cola Company High-potency sweetener composition with phytosterol and compositions sweetened therewith
US8524304B2 (en) * 2005-11-23 2013-09-03 The Coca-Cola Company High-potency sweetener composition with probiotics/prebiotics and compositions sweetened therewith
US9144251B2 (en) * 2005-11-23 2015-09-29 The Coca-Cola Company High-potency sweetener composition with mineral and compositions sweetened therewith
CA2629556A1 (en) * 2005-11-23 2007-07-19 The Coca Cola Company Synthetic sweetener compositions with improved temporal profile and/or flavor profile, methods for their formulation, and uses
US20100093861A1 (en) * 2006-09-15 2010-04-15 Stevia Aps Treatment of insulin resistance or diseases associated with insulin resistance
US8017168B2 (en) 2006-11-02 2011-09-13 The Coca-Cola Company High-potency sweetener composition with rubisco protein, rubiscolin, rubiscolin derivatives, ace inhibitory peptides, and combinations thereof, and compositions sweetened therewith
US20080107787A1 (en) * 2006-11-02 2008-05-08 The Coca-Cola Company Anti-Diabetic Composition with High-Potency Sweetener
US9101161B2 (en) * 2006-11-02 2015-08-11 The Coca-Cola Company High-potency sweetener composition with phytoestrogen and compositions sweetened therewith
WO2008134828A2 (en) 2007-05-04 2008-11-13 Katholieke Universiteit Leuven Tissue degeneration protection
MY155722A (en) * 2007-12-03 2015-11-30 Dsm Ip Assets Bv Novel nutraceutical compositions containing stevia extract or stevia extract constituents and uses thereof
WO2009071099A1 (en) * 2007-12-05 2009-06-11 Aarhus Universitet Elevation of the plasma hdl-cholesterol level
EP2456450A1 (en) * 2009-07-21 2012-05-30 DSM IP Assets B.V. Stevia extract or steviol for hair care
WO2011033524A2 (en) 2009-08-04 2011-03-24 Laila Nutraceuticals Agents from ficus hispida for the amelioration of metabolic syndrome and related diseases
US20110189360A1 (en) * 2010-02-04 2011-08-04 Pepsico, Inc. Method to Increase Solubility Limit of Rebaudioside D in an Aqueous Solution
KR101759767B1 (ko) * 2011-03-18 2017-07-19 페브리스 바이오-텍 리미티드 다중-약물 내성 말라리아를 치료하기 위한 조성물 및 방법
WO2014173418A1 (en) 2013-04-23 2014-10-30 Aarhus Universitet Compositions for use in restoring muscle glycogen and/or muscle mass
RU2525593C1 (ru) * 2013-05-24 2014-08-20 Государственное бюджетное образовательное учреждение дополнительного профессионального образования "Новокузнецкий государственный институт усовершенствования врачей" Министерства здравоохранения Российской Федерации Способ комплексного лечения артериальной гипертонии при метаболических нарушениях
TWI516474B (zh) 2013-05-27 2016-01-11 中央研究院 良薑化合物及其類似物之合成
SG11201510062VA (en) 2013-06-10 2016-01-28 Suntory Holdings Ltd Plant extract containing diketopiperazine and method for producing same
WO2017018404A1 (ja) * 2015-07-27 2017-02-02 サントリーホールディングス株式会社 環状ジペプチド及び甘味料を含有する組成物
CN112716929B (zh) * 2015-09-10 2023-03-31 东莞市凯法生物医药有限公司 贝壳杉烷类化合物在治疗心室增大及重构的药物应用
AU2017345605B2 (en) 2016-10-20 2022-04-14 The Coca-Cola Company Diterpene glycosides isolated from Stevia, compositions and methods
CN108159034B (zh) * 2018-02-12 2019-10-11 东南大学 异甜菊醇在制备治疗非酒精性脂肪性肝病药物中的应用
JPWO2020218382A1 (https=) * 2019-04-26 2020-10-29
CN111357979A (zh) * 2019-12-26 2020-07-03 浙江欧谱生物科技有限公司 抑制高脂引起的肥胖及骨丢失的保健食品组合物及其应用
CN111233702A (zh) * 2020-01-20 2020-06-05 中国科学院昆明植物研究所 先花铃子香素a衍生物与其药物组合物及其制备方法和应用

Family Cites Families (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4626441B1 (en) * 1983-10-06 1991-02-19 Dietetic frozen desserts containing aspartame
JPS63146813A (ja) * 1986-12-11 1988-06-18 Toa Nenryo Kogyo Kk ジテルペン系化合物を含んで成る制癌剤
GB9022543D0 (en) * 1990-10-17 1990-11-28 Wellcome Found Antibody production
EP0565785A1 (en) 1992-04-07 1993-10-20 Harry H. Leveen Use of glucose transport inhibitors for the treatment for acne
FR2695317B1 (fr) * 1992-09-07 1995-03-10 Monal Lab Composition apte à stimuler la sécrétion d'insuline destinée au traitement du diabète non insulino-dépendant.
JPH0813251B2 (ja) * 1993-07-14 1996-02-14 長岡香料株式会社 鉄及び又はマグネシウム及び又はカルシウムを含む呈味改善液
CN1094580A (zh) * 1994-01-06 1994-11-09 贾玉海 降糖糊
US5545414A (en) * 1995-03-22 1996-08-13 Abbott Laboratories Cholesterol lowering food product
JPH08325156A (ja) * 1995-06-01 1996-12-10 Ichimaru Pharcos Co Ltd ステビオール配糖体含有皮膚外用剤及び飲食品
JPH0952825A (ja) * 1995-06-09 1997-02-25 Taisho Pharmaceut Co Ltd 解熱鎮痛剤
CN1148476A (zh) * 1995-10-20 1997-04-30 王国安 一种降糖保健食品添加剂及其配制方法
US7091183B1 (en) * 1996-12-03 2006-08-15 Boston Medical Center Corporation Specific antagonists for glucose-dependent insulinotropic polypeptide (GIP)
CN1065753C (zh) * 1996-12-04 2001-05-16 上海绿泰宝营养保健品有限公司 降糖冲剂及其制备方法
CN1062722C (zh) * 1997-04-04 2001-03-07 青岛海洋大学 双纤维降糖粉及其制造方法
ATE201139T1 (de) * 1997-06-13 2001-06-15 Novo Nordisk As Neue dosierung für diabetes type 2
US5980902A (en) * 1998-03-26 1999-11-09 Pharma Terra, Inc. Compositions for treating and preventing diabetes, impaired glucose tolerance and related symptoms, and methods for preparing and using such compositions
CN1184895C (zh) * 1998-07-16 2005-01-19 阿龙·塔博尔 大豆组合物及其促进健康的应用
US20030113390A1 (en) * 1998-11-25 2003-06-19 Hoie Lars Henrik Composition comprising soy protein, dietary fibers and a phytoestrogen compound and use thereof in the prevention and/or treatment of various diseases
WO2001056959A1 (en) 2000-02-01 2001-08-09 Stevia Aps A substance for the use in a dietary supplementation or for the preparation of a medicament for the treatment of non-insulin dependent diabetes mellitus, hypertension and/or the metabolic syndrome
EP1361870A2 (en) 2001-02-01 2003-11-19 Nutri Pharma ASA A substance for use in a dietary supplement or for the preparation of a medicament for the treatment of non-insulin dependent diabetes mellitus, hypertension and/or the metabolic syndrome
US20090232913A1 (en) 2005-05-02 2009-09-17 Momir Mikov Composition for the Control of Cholesterol Levels
ATE445408T1 (de) * 2005-10-20 2009-10-15 Ghc Res Dev Corp Verwendung von prolactin in der prophylaktischen krebstherapie
US20100093861A1 (en) * 2006-09-15 2010-04-15 Stevia Aps Treatment of insulin resistance or diseases associated with insulin resistance

Similar Documents

Publication Publication Date Title
JP2003521528A5 (https=)
WO2002065985A3 (en) Methods of treating diabetes mellitus
WO2004080401A3 (en) Oral insulin therapies and protocol
WO2004028469A3 (en) Docohexaenoic acid for improved glycemic control
NO20053537L (no) Preparater og fremgangsmater for forebyggelse og kontroll av insulinindusert hypoglycemi.
NO20003051L (no) Metode for administrering av AspB28-humant insulin
EP2330092A3 (en) Medicament comprising steviol or isosteviol for the treatment of non-insulin dependent diabetes mellitus, hypertension and/or the metabolic syndrome
WO2003079979A3 (en) Method for treating congestive heart failure
MXPA03006217A (es) Sistema de administracion espaciada de farmacos.
NO20053041L (no) Behandling av diabetes.
MXPA05007470A (es) Metodo para reducir la morbilidad y mortalidad cardiovascular en pacientes prediabeticos y pacientes con diabetes de tipo 2.
TWI406666B (zh) Niu Zhangzhi for the treatment of diseases
BR0211894A (pt) Métodod de minimização e de redução dos nìveis médios de glucose, de tratamento de uma condição médica causada por nìveis elevados de glucose no sangue e de redução do valor hba1c em paciente dependente de insulina
WO1999056723A3 (en) Hemoglobine-haptoglobin complexes for targeted drug delivery
NO20015932L (no) Fremgangsmåte til å behandle diabetes
WO2004010946A3 (en) Therapeutic treatment for the metabolic syndrome and type 2 diabetes
WO2005117937A3 (en) Alpha-1- acid glycoprotein for the treatment of diabetes
CA2487362A1 (en) Use of an interleukin 1 receptor antagonist and/or pyrrolidinedithiocarbamate for the treatment or prophylaxis of type 2 diabetes
CA2344910A1 (en) Method for treating renal disease, and pharmaceutical composition for treating renal disease
Haak et al. Fenofibrate improves microcirculation in patients with hyperlipidemia
RU96115219A (ru) Способ лечения больных сахарным диабетом
Zhang et al. The use of nicardipine for electroconvulsive therapy: a dose-ranging study
WO2006004696A3 (en) Compositions and methods for the prevention and control of insulin-induced hypoglycemia
KR20230143978A (ko) 시클로-히스프로를 유효성분으로 포함하는 당뇨병 예방 또는 치료용 약제학적 제제
EP1033133A4 (en) COMPOSITION FOR TREATING DIABETES AND METHOD FOR TREATING DIABETES